# A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

> **NCT07185776** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 203 (actual)

## Conditions studied

- Lipoprotein Disorder

## Interventions

- **DRUG:** HRS-5632 Injection
- **DRUG:** HRS-5632 Injection Placebo

## Key facts

- **NCT ID:** NCT07185776
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-10-21
- **Primary completion:** 2027-04
- **Final completion:** 2027-10
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07185776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07185776, "A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07185776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*